RxDoctor Payments Data

Chelsea Hawks, NP

Nurse Practitioner · Canandaigua, NYNPI 1518537067

Payments from drug & device makers

$7,633in general payments, 2019–2025

Across 387 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$2K
  • Biogen$373
  • Teva Pharmaceuticals USA, Inc.$272
  • Biohaven Pharmaceutical Holding Company Ltd.$205
  • Lilly USA, LLC$179
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$6929%
  • Food & beverage$6,80889%
  • Education$1322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,633 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$26,727
Medicare patients
177
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate87$125,624
TecfideraDimethyl Fumarate11$102,668
BriviactBrivaracetam56$102,540
IngrezzaValbenazine Tosylate12$90,963
Teriflunomide35$76,810
Ajovy AutoinjectorFremanezumab-Vfrm51$55,305
Aimovig AutoinjectorErenumab-Aooe55$50,297
Dimethyl Fumarate24$50,053
NuplazidPimavanserin Tartrate11$45,595
QuliptaAtogepant43$45,327
RytaryCarbidopa/Levodopa38$43,192
Emgality PenGalcanezumab-Gnlm39$30,109
UbrelvyUbrogepant26$28,205
KeppraLevetiracetam19$22,033
Carbamazepine ErCarbamazepine82$15,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$157$125,62487 claims
BiogenTecfidera$373$102,66811 claims
UCB, Inc.Briviact$102$102,54056 claims
Neurocrine Biosciences, Inc.Ingrezza$68$90,96312 claims
AbbVieQulipta, Ubrelvy$2,328$73,53269 claims
Acadia Pharmaceuticals IncNuplazid$67$45,59511 claims
Amneal Pharmaceuticals LLCRytary$121$43,19238 claims
SK Life Science, Inc.Xcopri$91$12,31611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →